EXTH-43. DIFFERENTIATED PHARMACOLOGY OF THE IMIPRIDONE ONC201, THE FIRST SELECTIVE DRD2/3 ANTAGONIST IN CLINICAL NEURO-ONCOLOGY

ONC201, founding member of the imipridone class of compounds, has demonstrated evidence of tumor shrinkage along with exceptional safety in recurrent glioblastoma patients. In this study, we identified and characterized a previously unknown binding target of ONC201. BANDIT – a machine learning-based...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Madhukar, Neel, Prabhu, Varun Vijay, Anantharaman, Lakshmi, Sulli, Chidananda, Davidson, Edgar, Deacon, Sean, Tarapore, Rohinton, Rucker, Joseph, Charter, Neil, Doranz, Benjamin, Oster, Wolfgang, Elemento, Olivier, Free, R Benjamin, Sibley, David, Allen, Joshua E
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692326/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.335
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items